Company intelligence / Profile preview

Incline Therapeutics

Redwood City, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: NDA

Overview

IONSYS completed Phase III trials and had prior approvals in the US and EU. At time of acquisition by The Medicines Company, it awaited supplemental regulatory approval due to new safety features. No additional clinical results as an independent company after acquisition.[1][3]

Therapeutic areas: Other
Modalities: Drug-device combination (fentanyl iontophoretic transdermal system)
Industry: Biotech

Drug pipeline

1 asset

fentanyl

NDA

Indications: Acute postoperative pain

Partnerships

Cadence Pharmaceuticals held an option agreement to acquire Incline prior to its sale to The Medicines Company.[8]

Beyond the preview

Go deeper on Incline Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incline Therapeutics.

Explore the full profile